Chronic myeloid leukemia: Current strategies for diagnosis, therapy and follow-up;Chronische myeloische Leukamie. Aktuelle Strategien zur Diagnostik, Therapie und Verlaufskontrolle

Internist

Volumn 37, Issue 10, 1996, Pages 1013-1021

  Hochhaus, A ^a,b   Hehlmann, R ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYTARABINE; HYDROXYUREA; ABELSON KINASE; BCR ABL PROTEIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER DIAGNOSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; FOLLOW UP; HUMAN; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; BONE MARROW TRANSPLANTATION; CHROMOSOME ABERRATION; GENETICS; LEUKOCYTE COUNT; MORTALITY; MYELOID LEUKEMIA; SURVIVAL RATE;

BONE MARROW TRANSPLANTATION; CHROMOSOME ABERRATIONS; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LEUKOCYTE COUNT; PROTO-ONCOGENE PROTEINS C-ABL; SURVIVAL RATE;

EID: 0029805334     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Allan NC, Richards SM, Shepherd PC (1995) UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 345: 1392-1397
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H., Sultan C, Cox C (1994) The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87: 746-754
3. Bentz M, Cabot G, Moos M, Speicher MR, Ganser A, Lichter P, Döhner H (1994) Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization. Blood 83: 1922-1928
4. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P (1995) Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 88: 3118-3122
5. Carella AM, Frassoni F, Pollicardo N, Pungolino E, Ferrero R, Vasallo F, Soracco M, Giordano D, Figari O, Benvenuto F, Florio G, Carlier P, Valbonesi M (1995) Philadelphia-chromosome-negative peripheral stem cells can be molilized in the early phase of recovery after myelosuppressive chemotherapy in Philadelphia-chromosome-positive acute lymphoblastic leukaemia. Br J Haematol 89: 535-538
6. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM (1993) Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82: 1929-1936
7. Cross NCP, Melo JV, Feng L, Goldman JM (1994) An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 8: 186-189
8. Georgii A, Vykoupil KF, Buhr T, Choritz H, Dohler U, Kaloutsi V, Werner M (1990) Chronic myeloproliferative disorders in bone marrow biopsies. Pathol Res Pract 186: 3-27
9. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A, et al (1993) Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82: 2235-2238
10. Gratwohl A, Hermans J for the Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT) (1996) Allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 17 [Suppl 3]:S7-S9
11. Guo JQ, Lian JY, Xian YM, Lee MS, Deisseroth AB, Stass SA, Champlin RE, Talpaz M, Wang JY, Arlinghaus RB (1994) BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood 83: 3629-3637
12. Hasford J, Baccarani M, Hehlmann R, Ansari H, Tura S, Zuffa E (1996) Interferon-α and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-α. Blood 88: 5384-5391
13. Hehlmann R, Heimpel H, Hasford J and the German CML Study Group (1993) Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 82: 398-407
14. Hehlmann R, Heimpel H, Hasford J and the German CML Study Group (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 84: 4064-4077
15. Hehlmann R, Heimpel H, Kolb HJ and the German CML Study Group (1993) The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1. Leuk Lymphoma 11 [Suppl 1]: 159-168
16. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP (1996) Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood 87: 1549-1555
17. Hochhaus A, Lin F, Reiter A, Skladny H, van Rhee F, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP (1995) Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α. Br J Haematol 91: 126-131
18. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M (1996) Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 87: 3069-3081
19. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M, and the Leukemia Service (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 122: 254-261
20. Kolb HJ, Schattenberg A, Goldman JM and the European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86: 2041-2050
21. Mahon FX, Faberes C, Montastruc M, Si-Mour S, Boiron JM, Marit G, Bilhou-Nabera C, Cony-Makhoul P, Pigneux A, Bernard P, Brouslet A, Reiffers J (1996) High response rate using recombinant interferon-alpha in patients with newly diagnosed chronic myeloid leukemia. Bone Marrow Transplant 17 [Suppl 3]: S33-S37
22. Melo JV (1996) The molecular biology of chronic myeloid leukaemia. Leukemia 10: 751-756
23. Ohnishi K, Ohno R, Tomonaga M and the Kouseisho Leukemia Study Group (1995) A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86: 906-916
24. Reiter A, Skladny H, Hochhaus A. Schultheis B, Bartram CR, Heimpel H, Hehlmann R (1995) Comparison between cytogenetics and quantitative Southern blot analysis for monitoring interferon a treatment in CML-patients. Blood 86 [Suppl 1]:527a (abstract)
25. Seong DC, Kantarjian HM, Ro JY, Talpaz M, Xu J, Robinson JR, Deisseroth AB, Champlin RE, Siciliano MJ (1995) Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 86: 2343-2349
26. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, Rozman C (1984) Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63: 789-799
27. Statistisches Bundesamt (1994) Sterbefälle nach Todesursachen in Deutschland
28. Thaler J, Gastl G, Fluckinger T and the Austrian Biological Response Modifier (BRM) Study Group (1996) Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long term results of a multicenter phase-II study. Ann Hematol 72: 349-355
29. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330: 820-825
30. Verschraegen CF, Talpaz M, Hirsch Ginsberg CF, Pherwani R, Rios MB, Stass SA, Kantarjian HM (1995) Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. Blood 85: 2705-2710